NCT07397910Not yet recruiting
Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection
Clinical Trial to Analyze the Effectiveness of a Natural Compound on Chronic Immune-mediated Inflammatory Status in Subjects Who Have Had SARS-CoV-2 Infection.
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 25 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- Universidad Católica San Antonio de Murcia
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07397910
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Feb 2026 to the primary completion date, Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment.
Other illness
- Subjects with an underlying disease that explains the clinical manifestations.
- Presence of chronic inflammatory diseases.
- Subjects with acute infections.
- Hypersensitivity or intolerance to any of the components of the study products.
- Severe or terminal illnesses.
Other
- Excessive alcohol consumption.
- Use of any nutraceutical or dietary supplement.
- Subjects with a body mass index (BMI) over 32.
- Pregnant or lactating women.
Who the study is looking for
- Subjects of both sexes.
- Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA.
- Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness.
- No history of sequelae from a severe acute illness.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCAM HiTech, Sport & Health Innovation Hub Coordinator of this site? Confirm its status | Murcia | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.